 The changes in the manufacturing process of C1-esteraseremmer-N, compared to Cetor the currently marketed C1-inhibitor product, nanofiltration and omission of hepatitis B immunoglobulin, most likely will not affect tolerability. The nanofiltration will provide more safety regarding viruses. 